热门资讯> 正文

木薯科学GAAP每股收益为-0.92美元

2025-08-14 19:41

Cassava Sciences press release (NASDAQ:SAVA): Q2 GAAP EPS of -$0.92.
Cash and cash equivalents were $112.4 million, with no debt, as of June 30, 2025. This compares to cash and cash equivalents of $128.6 million as of December 31, 2024.

More on Cassava Sciences

Cassava Sciences taps Joseph Hulihan as chief medical officer
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit
Financial information for Cassava Sciences

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。